Journal of Clinical Oncology, Vol 12, 1058-1062, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

S Cascinu, A Fedeli, E Del Ferro, S Luzi Fedeli and G Catalano
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy.

PURPOSE: To evaluate the effect of exogenous recombinant human erythropoietin (rHuEPO) on the increase of hemoglobin levels and on the transfusion requirements in patients with cisplatin (CDDP)-induced anemia, we performed a double-blind randomized trial with placebo. PATIENTS AND METHODS: One hundred patients with CDDP-associated anemia (hemoglobin level < 90 g/L) were randomized to receive either placebo (saline solution) or rHuEPO (100 U/kg body weight subcutaneously) three times per week. The end points of this study were the increase in hemoglobin levels to greater than 100 g/L after 3, 6, and 9 weeks and the effect on transfusion requirements. RESULTS: Ninety-nine of 100 patients were assessable for response and toxicity. In the rHuEPO arm, mean hemoglobin levels were statistically significantly increased after the third, sixth, and ninth weeks of therapy (101.1 +/- 9.0, 102.4 +/- 6.6, and 105.1 +/- 9.4 g/L, respectively) compared with the mean baseline value (86.3 +/- 6.2 g/L). In the placebo arm, there were no increases in mean hemoglobin levels at the third, sixth, and ninth weeks (81.0 +/- 5.2, 81.3 +/- 9.2, and 81.2 +/- 11 g/L, respectively) compared with the mean baseline value (87.3 +/- 5.2 g/L). Furthermore only 20% of patients required blood transfusions in the rHuEPO arm versus 56% of patients in the placebo arm (P = .01), with a mean units of blood transfused per patient of 0.30 in the rHuEPO arm and 1.8 in the placebo arm (P = .01). Treatment was well tolerated, with no significant side effects. CONCLUSION: CDDP-induced anemia is corrected by rHuEPO, which results in reduced blood transfusion requirements.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Tonelli, B. Hemmelgarn, T. Reiman, B. Manns, M. N. Reaume, A. Lloyd, N. Wiebe, and S. Klarenbach Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis Can. Med. Assoc. J., May 26, 2009; 180(11): E62 - E71. [Abstract] [Full Text] [PDF]

				P. Gascon Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications Oncologist, May 1, 2008; 13(suppl_3): 4 - 10. [Abstract] [Full Text] [PDF]

				M. Dicato Venous Thromboembolic Events and Erythropoiesis-Stimulating Agents: An Update Oncologist, May 1, 2008; 13(suppl_3): 11 - 15. [Abstract] [Full Text] [PDF]

				S. S Shord, J.M. Hamilton Jr, and S. Cuellar Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 5 - 22. [Abstract] [PDF]

				C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]

				J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714. [Abstract] [Full Text] [PDF]

				A. Engert Recombinant human erythropoietin in oncology: current status and further developments Ann. Onc., October 1, 2005; 16(10): 1584 - 1595. [Abstract] [Full Text] [PDF]

				R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]

				T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617. [Abstract] [Full Text] [PDF]

				J. Bohlius, S. Langensiepen, G. Schwarzer, J. Seidenfeld, M. Piper, C. Bennett, and A. Engert Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis J Natl Cancer Inst, April 6, 2005; 97(7): 489 - 498. [Abstract] [Full Text] [PDF]

				L. M. Wagner, C. A. Billups, W. L. Furman, B. N. Rao, and V. M. Santana Combined Use of Erythropoietin and Granulocyte Colony-Stimulating Factor Does Not Decrease Blood Transfusion Requirements During Induction Therapy for High-Risk Neuroblastoma: A Randomized Controlled Trial J. Clin. Oncol., May 15, 2004; 22(10): 1886 - 1893. [Abstract] [Full Text] [PDF]

				T Ng, G Marx, T Littlewood, and I Macdougall Recombinant erythropoietin in clinical practice Postgrad. Med. J., July 1, 2003; 79(933): 367 - 376. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology J. Clin. Oncol., October 1, 2002; 20(19): 4083 - 4107. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood, September 18, 2002; 100(7): 2303 - 2320. [Abstract] [Full Text] [PDF]

				J. Vansteenkiste, R. Pirker, B. Massuti, F. Barata, A. Font, M. Fiegl, S. Siena, J. Gateley, D. Tomita, A. B. Colowick, et al. Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy J Natl Cancer Inst, August 21, 2002; 94(16): 1211 - 1220. [Abstract] [Full Text] [PDF]

				M. S. Gordon Managing Anemia in the Cancer Patient: Old Problems, Future Solutions Oncologist, August 1, 2002; 7(4): 331 - 341. [Abstract] [Full Text] [PDF]

				L. M. Itri Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2289 - 2293. [Full Text] [PDF]

				J. Seidenfeld, M. Piper, C. Flamm, V. Hasselblad, J. O. Armitage, C. L. Bennett, M. S. Gordon, A. E. Lichtin, J. L. Wade III, S. Woolf, et al. Epoetin Treatment of Anemia Associated With Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials J Natl Cancer Inst, August 15, 2001; 93(16): 1204 - 1214. [Abstract] [Full Text] [PDF]

				G. A Curt Fatigue in cancer BMJ, June 30, 2001; 322(7302): 1560 - 1560. [Full Text]

				T. J. Littlewood, E. Bajetta, J. W.R. Nortier, E. Vercammen, and B. Rapoport Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Oncol., June 1, 2001; 19(11): 2865 - 2874. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, J. Seidenfeld, M. Piper, N. Aronson, A. Lichtin, and T. J. Littlewood Erythropoietin: A Paradigm for the Development of Practice Guidelines Hematology, January 1, 2001; 2001(1): 10 - 30. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				I. Ray-Coquard, A. Le Cesne, M. T. Rubio, J. Mermet, C. Maugard, A. Ravaud, C. Chevreau, C. Sebban, T. Bachelot, P. Biron, et al. Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens J. Clin. Oncol., September 1, 1999; 17(9): 2840 - 2840. [Abstract] [Full Text] [PDF]

				J. T. Estrin, L. Schocket, R. Kregenow, and D. H. Henry A Retrospective Review of Blood Transfusions in Cancer Patients with Anemia Oncologist, August 1, 1999; 4(4): 318 - 324. [Abstract] [Full Text]

				T. Fjornes Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 22 - 31. [Abstract] [PDF]

				R. K. Portenoy and L. M. Itri Cancer-Related Fatigue: Guidelines for Evaluation and Management Oncologist, February 1, 1999; 4(1): 1 - 10. [Abstract] [Full Text]

				A. Varan, M. Buyukpamukcu, T. Kutluk, and C. Akyuz Recombinant Human Erythropoietin Treatment for Chemotherapy-related Anemia in Children Pediatrics, February 1, 1999; 103(2): 16e - 16. [Abstract] [Full Text]

				T. G Davidson Predictive models for response to recombinant human erythropoietin (rhEPO) in cancer patients Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4_suppl): S25 - S27. [Abstract] [PDF]

				L. D. Mastro and M. Venturini Strategies for the Use of Epoetin Alfa in Breast Cancer Patients Oncologist, October 1, 1998; 3(5): 314 - 318. [Abstract] [Full Text]

				F. Corazza, Y. Beguin, P. Bergmann, M. Andre, A. Ferster, C. Devalck, P. Fondu, M. Buyse, and E. Sariban Anemia in Children With Cancer Is Associated With Decreased Erythropoietic Activity and Not With Inadequate Erythropoietin Production Blood, September 1, 1998; 92(5): 1793 - 1798. [Abstract] [Full Text] [PDF]

				M. Cazzola, F. Mercuriali, and C. Brugnara Use of Recombinant Human Erythropoietin Outside the Setting of Uremia Blood, June 15, 1997; 89(12): 4248 - 4267. [Full Text] [PDF]